It our strategy to exit the platforms (MRI diagnostic contrast reagents and therapeutic medical devices)

independently to maximize shareholder value. We will exit the MRI contrast reagents business when

mature and generating sufficient cash flow to fund further development of higher-margin therapeutic

device products, in a range of cancer indications.

Fortis Oncology was formed in August, 2013 to commercialize advanced nanomaterial-containing medical devices and diagnostic products for the photothermal ablation of tumors. Fortis acquired global licensing rights to intellectual property developed by leading researchers at Wake Forest University School of Medicine. Wake Forest Innovations and Angels led Fortis’ seed round. Prior to Fortis’ acquisition of the IP, more than 5 years of preclinical work was completed, including the demonstration of proof-of-concept in large animal in vivo clinical studies. Studies demonstrated ablation of primary tumor as well as the destruction of metastatic cancer stem cells. Our aim is to bring advanced, nanothermal products to market approval that not only destroy cancer, but spare healthy tissue, in a fraction of the time required by conventional therapies and in doing so, change the face of cancer treatment as we know it forever. Fortis is now seeking investment for what will be a sustainable, profitable business.

The company is initiating important re-

search and clinical projects with leading

institutions including:

Wake Forest Medical School

MD Andersen Cancer Center

Vanderbilt University

University of Pittsburgh Medical Center

Memorial Sloan-Kettering

Mount Sinai Medical Center

University of Pennsylvania

National Cancer Institute

Paul Rohricht MS MBA, Founder & CEO

John Stewart MD, Founder & CMO

Nicole Levi-Polychenko PhD, Founder &

CSO

Paul Rohricht MS MBA, CEO

+1 (704)237-0213

paulrohricht@fortisoncology.com

www.fortisoncology.com ©2013 Fortis Oncology. All rights reserved

This document may contain forward-looking statements.

Fortis Oncology is currently focused on

three specific product development

initiatives to diagnose and treat kidney,

prostate, soft-tissue neoplasms, bone

neoplasms, and interperitoneal

cancers. Products include:

Advanced MRI contrast reagents;

Medical devices for the thermal

ablation of cancers;

Medical devices for the thermal

ablation of cancers in which

MWCNTs are functionalized with

tumorigenic APIs.

http://www.pnas.org/content/

Fortis Oncology was awarded US patents 8,252,772

(“Hyperthermic Technologies and Uses Thereof”) and US

8,501,233 (“Compositions and Methods for Treating Can-

cer”). In addition, we have an extensive IP estate in vari-

ous stages of prosecution in leading worldwide markets

that also include thermal ablation with drug delivery by

MWCNT’s.